New York State Common Retirement Fund Sells 5,804 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

New York State Common Retirement Fund reduced its stake in Arcus Biosciences, Inc. (NYSE:RCUS) by 15.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 32,755 shares of the company’s stock after selling 5,804 shares during the quarter. New York State Common Retirement Fund’s holdings in Arcus Biosciences were worth $1,142,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in RCUS. BVF Inc. IL raised its holdings in Arcus Biosciences by 49.1% in the 2nd quarter. BVF Inc. IL now owns 2,797,822 shares of the company’s stock worth $76,828,000 after purchasing an additional 921,700 shares during the period. FMR LLC raised its holdings in Arcus Biosciences by 38.4% in the 2nd quarter. FMR LLC now owns 3,091,165 shares of the company’s stock worth $84,883,000 after purchasing an additional 857,505 shares during the period. BlackRock Inc. increased its stake in Arcus Biosciences by 19.0% in the 2nd quarter. BlackRock Inc. now owns 4,038,728 shares of the company’s stock worth $110,902,000 after buying an additional 645,082 shares in the last quarter. State Street Corp increased its stake in Arcus Biosciences by 24.0% in the 2nd quarter. State Street Corp now owns 2,685,701 shares of the company’s stock worth $73,749,000 after buying an additional 520,307 shares in the last quarter. Finally, Woodline Partners LP increased its stake in Arcus Biosciences by 34.4% in the 2nd quarter. Woodline Partners LP now owns 1,663,568 shares of the company’s stock worth $45,682,000 after buying an additional 425,838 shares in the last quarter. 62.89% of the stock is currently owned by institutional investors.

RCUS opened at $35.81 on Friday. The firm has a market cap of $2.52 billion, a P/E ratio of -8.73 and a beta of 0.84. Arcus Biosciences, Inc. has a 12 month low of $22.36 and a 12 month high of $49.10. The stock has a 50-day moving average of $41.58 and a 200 day moving average of $35.14.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Monday, November 8th. The company reported ($1.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.13) by $0.02. The company had revenue of $9.46 million during the quarter, compared to analyst estimates of $9.27 million. Arcus Biosciences had a negative return on equity of 48.12% and a negative net margin of 735.12%. During the same quarter last year, the business posted $0.03 earnings per share. Analysts predict that Arcus Biosciences, Inc. will post -4.36 earnings per share for the current year.

In other Arcus Biosciences news, CEO Terry J. Rosen sold 2,299 shares of the firm’s stock in a transaction dated Thursday, December 16th. The shares were sold at an average price of $39.82, for a total value of $91,546.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jennifer Jarrett sold 34,822 shares of the firm’s stock in a transaction dated Monday, December 20th. The stock was sold at an average price of $41.48, for a total transaction of $1,444,416.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,518 shares of company stock valued at $1,830,516. 19.71% of the stock is currently owned by company insiders.

A number of equities research analysts have issued reports on the company. Barclays increased their price target on Arcus Biosciences from $48.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, November 19th. Citigroup increased their price target on Arcus Biosciences from $42.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, November 19th. SVB Leerink reiterated an “outperform” rating on shares of Arcus Biosciences in a research note on Friday, January 7th. Mizuho increased their price target on Arcus Biosciences from $43.00 to $51.00 and gave the stock a “buy” rating in a research note on Tuesday, November 9th. Finally, The Goldman Sachs Group cut their price objective on Arcus Biosciences from $45.00 to $43.00 in a research report on Thursday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $61.88.

About Arcus Biosciences

Arcus Biosciences, Inc engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Featured Story: How to invest using market indexes

Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences, Inc. (NYSE:RCUS).

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.